Abstract
Background
PALB2 (Partner and Localizer of BRCA2) is recently recognized as a breast cancer predisposition gene. Germline loss-of-function mutations in PALB2 lead to increased breast cancer risk. Since the germline mutation frequency of PALB2 is much less than BRCA1/2, the distinct mutation spectrum of PALB2 is still obscure. To verify the utility of PALB2 genetic testing in Chinese population, we assessed the mutational frequency, spectrum, and predictors of the PALB2 gene in a sequential series of Chinese breast cancer patients from our Research DNA Bank.
Methods
We examined breast cancer samples (n = 2279) collected from 2000 through 2016 from Chinese patients who agreed to participate in research DNA banking. To identify the mutations, complete coding sequence and intron–exon boundaries of PALB2 were screened with Next-Generation Sequencing. Personal and family histories were synchronously collected for mutation identification.
Results
Among the 2279 breast cancer patients, 305 patients were familial breast cancer cases and the rest 1967 patients were sporadic breast cancer cases. PALB2 loss-of-function mutation carriers accounted for 1.31% (n = 4) and 0.56% (n = 11) in familial and sporadic breast cancer cohort separately. In total, 30 missenses, four nonsenses, three frameshifts, three splicings, and one inframe deletions of PALB2 were identified in this study. Among the deleterious mutations, PALB2 c.1744C>T, c.2748+1G>A, c.2749−1G>C, c.3114−1G>A were newly identified in sporadic breast cancer, and c.3271delC newly found in familial breast cancer. Based on in silico analysis, we found two potentially damaging missense variants with high frequency: c.1213C>G, c.3054G>C, and classified six new potentially damaging missense variants.
Conclusions
Our data presented the germline mutation status of PALB2 in Chinese breast cancer patients, suggesting that loss-of-function germline mutations of PALB2 are important in both familial and sporadic breast cancer. Clinically, these data may be helpful in genetic counseling of breast cancer patients with PALB2 germline mutation.
Similar content being viewed by others
References
Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM (2006) Control of BRCA2 Cellular and Clinical Functions by a Nuclear Partner, PALB2. Mol Cell 22(6):719–729
Sy SMH, Huen MSY, Zhu Y, Chen J (2009) PALB2 Regulates Recombinational Repair through Chromatin Association and Oligomerization. J Biol Chem 284(27):18302–18310
Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, Yu X (2009) PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response. Current Biol 19(6):524–529
Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T et al (2006) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nature Genet 39(2):165–167
Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen S-M, Rapakko K et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446(7133):316–319
Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F et al (2014) Breast-cancer risk in families with mutations in PALB2. New Eng J Med 371(6):497–506
Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman AR, Winer EP, Garber JE (2016) Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol 34(13):1460–1468
Casadei S, Norquist BM, Walsh T, Stray S, Mandell JB, Lee MK, Stamatoyannopoulos JA, King MC (2011) Contribution of Inherited Mutations in the BRCA2-Interacting Protein PALB2 to Familial Breast Cancer. Cancer Res 71(6):2222–2229
Teo Z, Park D, Provenzano E, Chatfield C, Odefrey F, Nguyen-Dumont T, Dowty J, Hopper JL, Goldgar DE, Southey MC (2013) Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families. Breast Cancer Res Treat 15(1):R17
Teo ZL, Sawyer SD, James PA, Mitchell G, Trainer AH, Lindeman GJ, Shackleton K, Cicciarelli L, Southey MC (2013) The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia. Fam Cancer 12(4):587–595
Southey M, Teo Z, Dowty J, Odefrey F, Park D, Tischkowitz M, Sabbaghian N, Apicella C, Byrnes G, Winship I et al (2010) A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res Treat 12(6):R109
Cao AY, Huang J, Hu Z, Li W-F, Ma Z-L, Tang L-L, Zhang B, Su F-X, Zhou J, Di G-H et al (2008) The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 114(3):457–462
Li YT, Jiang WH, Wang XW, Zhang MS, Zhang CG, Yi LN, WuwaliKhan F, Ayoufu A, Ou JH (2015) PALB2 mutations in breast cancer patients from a multi-ethnic region in northwest China. Eur J Med Res 20:85
Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, Sabbaghian N, Darnel A, Royer R, Poll A, Fafard E et al (2007) Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res 9(6):83
Southey MC, Winship I, Nguyen-Dumont T (2016) PALB2: research reaching to clinical outcomes for women with breast cancer. Hered Cancer Clin Pract 14:9
Southey M (2013) Teo, Winship I: PALB2 and breast cancer: ready for clinical translation! Appl Clin Genet 6:43–52
Nguyen-Dumont T, Hammet F, Mahmoodi M, Tsimiklis H, Teo ZL, Li R, Pope BJ, Terry MB, Buys SS, Daly M et al (2015) Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry. Breast Cancer Res Treat 149(2):547–554
Kim H, Cho DY, Choi DH, Oh M, Shin I, Park W, Huh SJ, Nam SJ, Lee JE, Kim SW (2017) Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer. Breast Cancer Res Treat 161(1):95–102
Acknowledgements
We acknowledge Dr. Joshua Sutikno of Zhejiang University School of Medicine for polishing the English of the whole paper. This study was supported by the funding of the Key Program of the Natural Science Foundation of Zhejiang Province (Grant No. LZ16H160002), and the Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there is no conflict of interests regarding the publication of this paper.
Rights and permissions
About this article
Cite this article
Zhang, K., Zhou, J., Zhu, X. et al. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer. Breast Cancer Res Treat 166, 865–873 (2017). https://doi.org/10.1007/s10549-017-4425-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-017-4425-z